Search results
AbbVie Announces Positive Topline Results from Phase 2 PICCOLO Trial Evaluating Mirvetuximab...
The Parsons Sun· 4 days agoPICCOLO trial met its primary endpoint of objective response rate (ORR)Data from the study will be presented at a future medical meeting
AI camera could help doctors identify serious infections
Medical Xpress· 5 days agoIt might soon be possible to measure a patient's pulse, breathing, and blood pressure simply by...
Anthrax case in Texas linked to butchering lamb that died unexpectedly
UPI· 3 days agoA Texas rancher caught the anthrax germ after butchering and consuming meat from a lamb that had...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 5 days agoFDA Approved Phase II/III Clinical Study of KPG-121 in Combination with Abiraterone as a First Line Treatment for mCRPC PR Newswire HEFEI, China, June 5, 2024 HEFEI, China, June 5, 2024 /PRNewswire/ -- Kangpu Biopharmaceuticals today announced that
This biodegradable material could be leaking PFAS into your garden
Bangor Daily News· 5 days agoOne of the most readily available options for mulching and creating weed barriers around the home...
An anti-inflammatory curbs spread of fungi causing serious blood infections
Science Daily· 6 days agoC. albicans, or candida, is known to cause yeast infections. In some cases, it develops into invasive candidiasis, a potentially fatal infection occurring mostly in patients with compromised ...
Theriva Biologics Receives Fast Track Designation From FDA For VCN-01 For Treating Metastatic...
Benzinga· 4 days agoTheriva™ Biologics TOVX is an immuno-oncology company developing oncolytic viruses, otherwise known...
Increased Heart Risks With Newer Prostate Cancer Drugs, Meta-Analysis Shows
MedPage Today· 4 days agoAdding ARSIs to ADT for advanced disease doubled the risk of high-grade CV events, death
Affimed (AFMD) Soars on Upbeat Follow-Up Data From NSCLC Study
Zacks· 6 days agoThe phase I/IIa AFM24-102 study is evaluating AFM24 in combination with Roche’s (RHHBY Quick...
Puma Biotechnology Announces Presentation of Findings from a Phase I/Ib Study of Alisertib in...
Benzinga· 7 days agoPuma Biotechnology, Inc. PBYI, a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal ...
